Article Text

Download PDFPDF

123 Real world data of treatment and outcome of patients with high grade AOC (advanced ovarian cancer) in Germany (QS Ovar)
  1. P Harter1,
  2. A Du Bois1,
  3. F Hilpert2,
  4. M Kerkmann3,
  5. J Sehouli4,
  6. S Mahner5,
  7. N De Gregorio6,
  8. L Hanker7,
  9. F Heitz1,
  10. F Marmé8,
  11. L Wölber2,9,
  12. L Holtmann3 and
  13. J Pfisterer10
  1. 1Ev. Kliniken Essen-Mitte, Gynecology and Gynecologic Oncology, Essen, Germany
  2. 2Jerusalem Krankenhaus, Onkologisches Therapiezentrum , Hamburg, Germany
  3. 3MMF GmbH, Dortmund, Germany
  4. 4Charité , Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Germany
  5. 5LMU University Hospital, Obstetrics and Gynecology, Munich, Germany
  6. 6SLK Kliniken, Frauenklinik, Heilbronn, Germany
  7. 7Universitätsklinikum Schleswig-Holstein, Campus Lübeck, , Gynecology and Obstetrics, Lübeck, Germany
  8. 8Medical Faculty Mannheim, Heidelberg University, Frauenklinik, Mannheim, Germany
  9. 9University Medical Center Hamburg-Eppendorf, Gynecology, Hamburg, Germany
  10. 10Zentrum für Gynäkologische Onkologie, Kiel, Germany


Introduction/Background*Recent and detailed data regarding treatment quality and outcome of patients with high grade AOC on a nationwide basis are largely unknown in Germany.

Methodology All German hospitals treating patients with ovarian cancer were asked to document all patients with first diagnosis in the third quarter in 2012 and 2016. Details of tumor, treatment and outcome were documented. This analysis is focusing on patients with AOC FIGO III/IV and the endpoint PFS (progression free survival) (OS data immature for 2016 cohort). As response rates were not documented, we defined a subcohort of patients without progressive disease within 3 months after end of chemotherapy as potential candidates for an additional maintenance therapy.

Result(s)*In total, 1010 patients with high grade AOC with a median age of 65 years were documented. 774/1010 (76.6%) were diagnosed with FIGO III disease and 947/1010 (93.8%) had high-grade serous histologic subtype. 915/1010 (90.6%) had primary cytoreductive surgery. Complete resection was achieved in 434/1010 (43.0%) at primary surgery and in 54/1010 (5.3%) at interval debulking surgery. Carboplatin/paclitaxel/bevacizumab (TCB) was the primary systemic therapy in 627/1010 (62.1%) and carboplatin/paclitaxel (TC) in 292/1010 (28.9%). Median PFS in patients with primary surgery and complete resection was 29.7 months (95% CI 27.4-34.2) compared to 17.2 months (95% CI 15.7-18.9) in all other patients (p<0.001: HR 0.49, 95% CI 0.42-0.57). Median PFS in patients with TCB was 23.3 months (95% CI 22.0-25.3) and 18.5 months (95% CI 15.7-21.9) in patients treated with TC (p=0,083: HR 0.87, 95% CI 0.74-1.02). In total, 899/1010 (89%) did not progress within 3 months.

Conclusion*Most patients in Germany with high grade AOC are treated with primary surgery followed by carboplatin/paclitaxel/bevacizumab. Depending on biomarker status most patients are potential candidates for a PARP-inhibitor maintenance therapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.